U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07226063) titled 'Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer' on Nov. 06.
Brief Summary: This research study is for people who were treated with tremelimumab and durvalumab for advanced liver cancer and who are currently receiving durvalumab. Participants in this study will receive a drug called zanzalintinib. They will also continue receiving durvalumab. Studies have shown that patients with advanced liver cancer who had tremelimumab and durvalumab may benefit from taking zanzalintinib while they are taking durvalumab. Zanzalintinib is an investigational drug. This means it has not been approved by t...